Gilles de la Tourette syndrome (TS) is a chronic neuropsychiatric disorder characterized by motor and vocal tics. First-line treatments for tics are antipsychotics and tic-specific behavioral therapies. However, due to a lack of trained therapists and adverse events of antipsychotic medication many patients seek alternative treatment options including cannabis. Based on the favorable results obtained from case studies on different cannabis-based medicines as well as two small randomized controlled trials using delta-9-tetrahydrocannabinol (THC), a group of scientists in Germany hypothesized that the cannabis extract Nabiximols (Sativex, 1:1 CBD, THC) can be regarded as a promising new and safe treatment strategy in TS.
Despite of the continuous loss, GW pharmaceuticals Ltd (NASDAQ:GWPH) is positive for the future of cannabis as many other advocates and decided to sponsor this experiment.